All In MedTech

Device Trial Radar · NCT07447414

Luminal Breast Cancer Cryoablation

Cryoablation for the Treatment of Luminal Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Lucía Graña LópezAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 3, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LUBRECA will evaluate the safety and efficacy of cryoablation with liquid nitrogen to treat cT1cN0 luminal breast cancer diagnosed in postmenopausal women

Conditions

  • Breast Cancer
  • Breast Cancer (Early Breast Cancer)

Interventions

  • Cryoablation with liquid nitrogen (Prosense® system)Device

    The appropriate cryoprobe (10G or 13G) will be selected depending on the size of the tumor. After injecting local anesthesia, the cryoprobe will be inserted along the longest diameter of the lesion. The tip of the needle will be advanced so that the freezing center is located in the middle of the tumor. Two freezing cycles will be performed, separated by a thawing cycle, all three of the same duration, which depends on the size of the tumor. The goal is a freezing volume with a lethal zone covering the lesion and a safety margin of at least 1 cm. Ultrasound allows real-time monitoring of the expansion of the ice ball during cryoablation. To avoid burning the skin, we will inject warm sterile saline solution when the distance between the ice and the skin surface is less than 0.5 cm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cryoablation success rateTime frame: 30days after cryoablation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Lucus Augusti

    Lugo, Lugo, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.